The market for NASH, a severe form of nonalcoholic fatty liver disease (NAFLD), offers substantial commercial opportunity to drug developers owing to the lack of approved agents and the disease’s large and growing prevalence. The body of evidence for the significant burden that the disease places on healthcare systems is accumulating, particularly with respect to the increased risk of cardiovascular diseases, liver failure, and NASH’s potential to quickly become the leading reason for liver transplantation. The lack of treatment options and limited awareness of the disease and its complications have kept diagnosis and treatment rates low. Despite guidelines recommending certain off-label medications, prescribing is usually limited to specialists caring for patients with more-advanced disease. However, with more education about NASH, the development of novel diagnostic tools, and the anticipated approval of therapies to treat the disease, diagnosis and treatment rates will increase and drive growth of the overall therapy market. Over the 2021-2031 forecast period, this market will see the launches of the first agents from a rich pipeline of emerging therapies, fueling massive market expansion.
Questions answered:
What is the prevalence of NASH, and what is driving the growth of this indication?
How is NASH being managed? With no approved medications, how are physicians using available prescription medications off-label to treat the disease?
Which emerging therapy will gain the greatest share in the nascent branded therapy market?
Where will Intercept’s obeticholic acid, Madrigal’s resmetirom, and Novo Nordisk’s semaglutide fit in the evolving NASH treatment paradigm?
CONTENT HIGHLIGHTS
Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, Japan.
Primary research: Nineteen country-specific interviews with thought-leading hematologists. Supported by survey data collected for this and other Clarivate research.
Epidemiology: Diagnosed prevalence of NASH by country; population segmentation by stage of fibrosis.
Emerging therapies: Coverage of select emerging therapies from preclinical to preregistration stages.
Market forecast features: 10-year, annualized, drug-level sales and patient share of key NASH therapies through 2031, segmented by brands and epidemiological subpopulations.
PRODUCT DESCRIPTION
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
SOLUTION ENHANCEMENT
Disease Landscape & Forecast features continual updates to provide timely insights and analyses as meaningful indication-specific news and events unfold. Additionally, Disease Landscape & Forecast introduces a new Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.